
Renal Denervation Market By Technology, By Product Type, By Indication And By End User ( Hospitals, Diagnostic Centers, Research And Academic Institutes), And Region - Global Forecast To 2028
7684
6th June 2019
226
PDF
The global renal denervation market is estimated to value at nearly US$ 0.24 Bn in 2019, and is expected to register a CAGR of 15.2 %. The Global renal denervation market is segmented on the basis of technology, product type, indication, end user, and region.
Renal Denervation Market: Introduction
Renal denervation is a type of minimally invasive procedure which involves endovascular access from femoral artery using a catheter-mounted device into the renal artery. The device uses radiofrequency ablation, pharmacologic ablation or ultrasound ablation for the treatment of resistant high blood pressure which is unable to control by medication.
Renal Denervation Market: Dynamics
Rising prevalence of serious health conditions such as high blood pressure or hypertension is major factors expected to drive growth of the global renal denervation market. Technological advancements to develop alternative technologies such as micro-infusion for renal denervation systems is expected to fuel growth of the global renal denervation market. Furthermore, increasing investments for innovations and research and development activities related to renal sympathetic denervation is expected to create a lucrative opportunity for growth of the global renal denervation market over the forecast period.
However, stringent regulatory norms for renal denervation devices, product recalls, and low reimbursements rates in developing countries are expected to hamper growth of the renal denervation market to a certain extent over the forecast period.
Increasing incidence of hypertension across the globe is a key factor expected to drive revenue growth of the global renal denervation market.
- According to the Centers for Disease Control and Prevention in 2018, around one of three adults in the US - or around 75 Mn individuals - had high blood pressure
- In January 2018, the American Heart Association estimated that nearly 103 Mn US adults suffering from high blood pressure
Increasing geriatric population across the globe has prompted the development of advanced renal denervation products to treat blood pressure, heart failure, diabetes, and renal failure more efficiently and improve quality of life.
- According to the World Population Prospects 2017 report published by the United Nations, the number of persons aged 80 years and over is projected to triple from 137 Million in 2017 to 425 Million by 2050. By 2100 in addition, this number is expected to increase to 909 Million, which is around seven times that of 2017
- According to the United Nations, there were approximately 962 Mn people aged 60 years and above globally in 2017, comprising 13% of the global population. This number is projected to increase to 1.4 Bn by 2030, and 2.1 Bn by 2050
Increasing number of clinical trials are ongoing and some new techniques being worked on, owing to higher demand for novel therapeutic treatment and medical devices, coupled with rising investment in research and development activities.
- In June 2019, National Institutes of Health (NIH), which is a US-based medical research center, announced a study of clinical Trial: A Phase 3, Multicenter, Blinded, Sham-Procedure Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, and is expected to complete by 2023
Global Renal Denervation Market Analysis, by Technology
Among the technology segments, the radiofrequency ablation segment is expected to account for major revenue share and is expected to maintain its dominance over the forecast period. The radiofrequency ablation segment is expected to register CAGR of over 15.8%.
The ultrasound ablation segment accounts for second highest share in terms of revenue in the near future. The ultrasound ablation segment is expected to register second highest CAGR of over 14.6%.
Global Renal Denervation Market Analysis, by Product Type
Among the product type segments, the catheters segment is expected to account for major revenue share and is expected to maintain its dominance over the forecast period. The catheters segment is expected to register CAGR of over 15.6%. The RF generator segment accounts for second highest share in terms of revenue in the near future. The RF generator segment is expected to register second highest CAGR of over 13.4%.
Global Renal Denervation Market Analysis, by Indication
Among the indication segments, the hypertension segment is accounted for the major revenue share and is expected to maintain its dominance over the forecast period. The hypertension segment is expected to register CAGR of over 15.3%.
Global Renal Denervation Market Analysis, by End User
Among the end user segments, the hospital segment is expected to account for major revenue share and is expected to maintain its dominance over the forecast period. The hospital segment is expected to register CAGR of over 15.9%. The heart failure segment accounts for second highest share in terms of revenue in the near future. The heart failure segment is expected to register second highest CAGR of over 13.6%.
Global Renal Denervation Market Analysis, by Region
Currently, the market in North America is dominating the global market in terms of revenue and is expected to maintain its dominance over the forecast period. Increasing research and development activities for the development of efficient devices in the countries in this region is a major factor expected to drive revenue growth of the North America renal denervation market over the next 10 years.
The Europe renal denervation market also registered significant growth in the global renal denervation market in the near future. The renal denervation market in the Asia Pacific is expected to grow at a moderate rate in terms of revenue over the forecast period. Increasing prevalence of lifestyle-related disorders such as diabetes and obesity in the countries in this region is expected to drive the growth of the market in the Asia Pacific. In addition, the increasing number of drug-resistant hypertension cases is expected to support revenue growth of renal denervation market in the Asia Pacific.
Global Renal Denervation Market Segmentation:
Global Renal Denervation Market Segmentation, by Technology:
- Ultrasound Ablation
- Radiofrequency Ablation
- Pharmacologic Ablation
Global Renal Denervation Market Segmentation, by Product Type:
- Catheters
- Single Electrode Catheter
- Multi-Electrode Catheter
- RF Generator
- Nerve Modifying Agents
Global Renal Denervation Market Segmentation, by Indication:
- Hypertension
- Heart Failure
- Diabetes
- Renal Failure
Global Renal Denervation Market Segmentation, by End User:
- Hospitals
- Specialty Clinics
- Research and Academic Institutes
- Ambulatory Care Centers
Global Renal Denervation Market Segmentation, by Region:
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
- Medtronic, Plc.
- Abbott Laboratories
- Boston Scientific Corporation
- Otsuka Holdings Co., Ltd.
- Cardinal Health, Inc.,
- Terumo Corporation
- Mercator Medsystems, Inc.
- Kona Medical, Inc.
- Cardiosonic Ltd.
- Ablative Solutions, Inc.
- SympleSurgical Inc.
- Chapter 1 Global Renal Denervation Market Overview
- 1.1 Introduction
- 1.2 Executive Summary
- 1.3 Drivers
- 1.4 Restraints for Renal Denervation Market
- 1.5 Opportunities for Renal Denervation Market
- 1.6 Trends for Renal Denervation Market
- 1.7 Supply Chain Analysis
- 1.8 Manufacturing Cost Analysis
- 1.9 Regulatory Scenario
- 1.1 Go to Market Strategy – Market Maturity
- 1.11 Hypertension Population based on Medtronic’s SPYRAL HTN ON-MED and OFF-MED Studies/Treatment
- 1.12 Global Renal Denervation Market Outlook (2012-2028)
- 1.12.1 Global Renal Denervation Revenue (US$ Mn) (2012-2019)
- 1.12.2 Global Renal Denervation Revenue (US$ Mn) (2020–2028)
- 1.13 Global Renal Denervation Revenue, by Regions
- 1.13.1 Global Renal Denervation Revenue (US$ Mn), by Region (2012-2019)
- 1.13.2 Global Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 1.14 Global Renal Denervation Revenue, by Technology
- 1.14.1 Global Renal Denervation Revenue (US$ Mn), by Technology (2012-2019)
- 1.14.2 Global Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 1.15 Global Renal Denervation Revenue, by Product Type
- 1.15.1 Global Renal Denervation Revenue (US$ Mn), by Product Type (2012-2019)
- 1.15.2 Global Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 1.16 Global Renal Denervation Revenue, by Indication
- 1.16.1 Global Renal Denervation Revenue (US$ Mn), by Indication (2012-2019)
- 1.16.2 Global Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 1.17 Global Renal Denervation Revenue, by End User
- 1.17.1 Global Renal Denervation Revenue (US$ Mn), by End User (2012-2019)
- 1.17.2 Global Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 1.18 Global Renal Denervation Market Share (%), 2013–2028
- 1.18.1 Global Renal Denervation Market Share (%), by Region
- 1.18.2 Global Renal Denervation Market Share (%), by Technology
- 1.18.3 Global Renal Denervation Market Share (%), by Product Type
- 1.18.4 Global Renal Denervation Market Share (%), by Indication
- 1.18.5 Global Renal Denervation Market Share (%), by End User
- Chapter 2 Global Renal Denervation Market Insights
- 2.1 Opportunity Map Analysis
- 2.2 PEST Analysis
- 2.3 PORTER’S Five Forces Analysis
- Chapter 3 North America Renal Denervation Market Outlook
- 3.1.1 North America Renal Denervation Revenue (US$ Mn) (2012-2019)
- 3.1.2 North America Renal Denervation Revenue (US$ Mn) (2020–2028)
- 3.2 North America Renal Denervation Revenue, by Regions
- 3.2.1 North America Renal Denervation Revenue (US$ Mn), by Region (2012-2019)
- 3.2.2 North America Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 3.3 North America Renal Denervation Revenue, by Technology
- 3.3.1 North America Renal Denervation Revenue (US$ Mn), by Technology (2012-2019)
- 3.3.2 North America Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 3.4 North America Renal Denervation Revenue, by Product Type
- 3.4.1 North America Renal Denervation Revenue (US$ Mn), by Product Type (2012-2019)
- 3.4.2 North America Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 3.5 North America Renal Denervation Revenue, by Indication
- 3.5.1 North America Renal Denervation Revenue (US$ Mn), by Indication (2012-2019)
- 3.5.2 North America Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 3.6 North America Renal Denervation Revenue, by End User
- 3.6.1 North America Renal Denervation Revenue (US$ Mn), by End User (2012-2019)
- 3.6.2 North America Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 3.7 North America Renal Denervation Market Share (%), 2013–2028
- 3.7.1 North America Renal Denervation Market Share (%), by Region
- 3.7.2 North America Renal Denervation Market Share (%), by Technology
- 3.7.3 North America Renal Denervation Market Share (%), by Product Type
- 3.7.4 North America Renal Denervation Market Share (%), by Indication
- 3.7.5 North America Renal Denervation Market Share (%), by End User
- Chapter 4 Europe Renal Denervation Market Overview
- 4.1 Europe Renal Denervation Market Outlook (2012-2028)
- 4.1.1 Europe Renal Denervation Revenue (US$ Mn) (2012-2019)
- 4.1.2 Europe Renal Denervation Revenue (US$ Mn) (2020–2028)
- 4.2 Europe Renal Denervation Revenue, by Regions
- 4.2.1 Europe Renal Denervation Revenue (US$ Mn), by Region (2012-2019)
- 4.2.2 Europe Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 4.3 Europe Renal Denervation Revenue, by Technology
- 4.3.1 Europe Renal Denervation Revenue (US$ Mn), by Technology (2012-2019)
- 4.3.2 Europe Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 4.4 Europe Renal Denervation Revenue, by Product Type
- 4.4.1 Europe Renal Denervation Revenue (US$ Mn), by Product Type (2012-2019)
- 4.4.2 Europe Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 4.5 Europe Renal Denervation Revenue, by Indication
- 4.5.1 Europe Renal Denervation Revenue (US$ Mn), by Indication (2012-2019)
- 4.5.2 Europe Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 4.6 Europe Renal Denervation Revenue, by End User
- 4.6.1 Europe Renal Denervation Revenue (US$ Mn), by End User (2012-2019)
- 4.6.2 Europe Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 4.7 Europe Renal Denervation Market Share (%), 2013–2028
- 4.7.1 Europe Renal Denervation Market Share (%), by Region
- 4.7.2 Europe Renal Denervation Market Share (%), by Technology
- 4.7.3 Europe Renal Denervation Market Share (%), by Product Type
- 4.7.4 Europe Renal Denervation Market Share (%), by Indication
- 4.7.5 Europe Renal Denervation Market Share (%), by End User
- 4.1 Europe Renal Denervation Market Outlook (2012-2028)
- Chapter 5 Asia Pacific Renal Denervation Market Overview
- 5.1 Asia Pacific Renal Denervation Market Outlook (2012-2028)
- 5.1.1 Asia Pacific Renal Denervation Revenue (US$ Mn) (2012-2019)
- 5.1.2 Asia Pacific Renal Denervation Revenue (US$ Mn) (2020–2028)
- 5.2 Asia Pacific Renal Denervation Revenue, by Regions
- 5.2.1 Asia Pacific Renal Denervation Revenue (US$ Mn), by Region (2012–2019)
- 5.2.2 Asia Pacific Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 5.3 Asia Pacific Renal Denervation Revenue, by Technology
- 5.3.1 Asia Pacific Renal Denervation Revenue (US$ Mn), by Technology (2012–2019)
- 5.3.2 Asia Pacific Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 5.4 Asia Pacific Renal Denervation Revenue, by Product Type
- 5.4.1 Asia Pacific Renal Denervation Revenue (US$ Mn), by Product Type (2012–2019)
- 5.4.2 Asia Pacific Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 5.5 Asia Pacific Renal Denervation Revenue, by Indication
- 5.5.1 Asia Pacific Renal Denervation Revenue (US$ Mn), by Indication (2012–2019)
- 5.5.2 Asia Pacific Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 5.6 Asia Pacific Renal Denervation Revenue, by End User
- 5.6.1 Asia Pacific Renal Denervation Revenue (US$ Mn), by End User (2012–2019)
- 5.6.2 Asia Pacific Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 5.7 Asia Pacific Renal Denervation Market Share (%), 2013–2028
- 5.7.1 Asia Pacific Renal Denervation Market Share (%), by Region
- 5.7.2 Asia Pacific Renal Denervation Market Share (%), by Technology
- 5.7.3 Asia Pacific Renal Denervation Market Share (%), by Product Type
- 5.7.4 Asia Pacific Renal Denervation Market Share (%), by Indication
- 5.7.5 Asia Pacific Renal Denervation Market Share (%), by End User
- 5.1 Asia Pacific Renal Denervation Market Outlook (2012-2028)
- Chapter 6 South America Renal Denervation Market Overview
- 6.1 South America Renal Denervation Market Outlook (2012-2028)
- 6.1.1 South America Renal Denervation Revenue (US$ Mn) (2012–2019)
- 6.1.2 South America Renal Denervation Revenue (US$ Mn) (2020–2028)
- 6.2 South America Renal Denervation Revenue, by Regions
- 6.2.1 South America Renal Denervation Revenue (US$ Mn), by Region (2012–2019)
- 6.2.2 South America Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 6.3 South America Renal Denervation Revenue, by Technology
- 6.3.1 South America Renal Denervation Revenue (US$ Mn), by Technology (2012–2019)
- 6.3.2 South America Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 6.4 South America Renal Denervation Revenue, by Product Type
- 6.4.1 South America Renal Denervation Revenue (US$ Mn), by Product Type (2012–2019)
- 6.4.2 South America Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 6.5 South America Renal Denervation Revenue, by Indication
- 6.5.1 South America Renal Denervation Revenue (US$ Mn), by Indication (2012–2019)
- 6.5.2 South America Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 6.6 South America Renal Denervation Revenue, by End User
- 6.6.1 South America Renal Denervation Revenue (US$ Mn), by End User (2012–2019)
- 6.6.2 South America Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 6.7 South America Renal Denervation Market Share (%), 2013–2028
- 6.7.1 South America Renal Denervation Market Share (%), by Region
- 6.7.2 South America Renal Denervation Market Share (%), by Technology
- 6.7.3 South America Renal Denervation Market Share (%), by Product Type
- 6.7.4 South America Renal Denervation Market Share (%), by Indication
- 6.7.5 South America Renal Denervation Market Share (%), by End User
- 6.1 South America Renal Denervation Market Outlook (2012-2028)
- Chapter 7 MEA Renal Denervation Market Overview
- 7.1 MEA Renal Denervation Market Outlook (2012-2028)
- 7.1.1 MEA Renal Denervation Revenue (US$ Mn) (2012–2019)
- 7.1.2 MEA Renal Denervation Revenue (US$ Mn) (2020–2028)
- 7.2 MEA Renal Denervation Revenue, by Regions
- 7.2.1 MEA Renal Denervation Revenue (US$ Mn), by Region (2012–2019)
- 7.2.2 MEA Renal Denervation Revenue (US$ Mn), by Region (2020–2028)
- 7.3 MEA Renal Denervation Revenue, by Technology
- 7.3.1 MEA Renal Denervation Revenue (US$ Mn), by Technology (2012–2019)
- 7.3.2 MEA Renal Denervation Revenue (US$ Mn), by Technology (2020–2028)
- 7.4 MEA Renal Denervation Revenue, by Product Type
- 7.4.1 MEA Renal Denervation Revenue (US$ Mn), by Product Type (2012–2019)
- 7.4.2 MEA Renal Denervation Revenue (US$ Mn), by Product Type (2020–2028)
- 7.5 MEA Renal Denervation Revenue, by Indication
- 7.5.1 MEA Renal Denervation Revenue (US$ Mn), by Indication (2012–2019)
- 7.5.2 MEA Renal Denervation Revenue (US$ Mn), by Indication (2020–2028)
- 7.6 MEA Renal Denervation Revenue, by End User
- 7.6.1 MEA Renal Denervation Revenue (US$ Mn), by End User (2012–2019)
- 7.6.2 MEA Renal Denervation Revenue (US$ Mn), by End User (2020–2028)
- 7.7 MEA Renal Denervation Market Share (%), 2013–2028
- 7.7.1 MEA Renal Denervation Market Share (%), by Region
- 7.7.2 MEA Renal Denervation Market Share (%), by Technology
- 7.7.3 MEA Renal Denervation Market Share (%), by Product Type
- 7.7.4 MEA Renal Denervation Market Share (%), by Indication
- 7.7.5 MEA Renal Denervation Market Share (%), by End User
- 7.1 MEA Renal Denervation Market Outlook (2012-2028)
- Chapter 8 Global Market Manufacturer Profiles
- 8.1 Cardinal Health, Inc.
- 8.1.1 Company Details
- 8.1.2 Business Overview
- 8.1.3 Product Portfolio
- 8.1.4 Financial Overview
- 8.1.5 Analysis & Outcomes
- 8.1.6 Key Development
- 8.1.7 SWOT Analysis
- 8.1.8 Contact Information
- 8.2 Abbott Laboratories
- 8.2.1 Company Details
- 8.2.2 Business Overview
- 8.2.3 Product Portfolio
- 8.2.4 Financial Overview
- 8.2.5 Analysis & Outcomes
- 8.2.7 SWOT Analysis
- 8.2.8 Contact Information
- 8.3 Medtronic, Plc.
- 8.3.1 Company Details
- 8.3.2 Business Overview
- 8.3.3 Product Portfolio
- 8.3.4 Financial Overview
- 8.3.5 Analysis & Outcomes
- 8.3.6 Key Development
- 8.3.7 SWOT Analysis
- 8.3.8 Contact Information
- 8.4 Otsuka Holdings Co., Ltd.
- 8.4.1 Company Details
- 8.4.2 Business Overview
- 8.4.3 Product Portfolio
- 8.4.4 Financial Overview
- 8.4.5 Analysis & Outcomes
- 8.4.6 Key Development
- 8.4.7 Contact Information
- 8.5 Boston Scientific Corporation
- 8.5.1 Company Details
- 8.5.2 Business Overview
- 8.5.3 Product Portfolio
- 8.5.4 Analysis & Outcomes
- 8.5.5 Sales Share (%) and Revenue (US$ Mn), by Geography, 2018
- 8.5.6 Contact Information
- 8.6 Terumo Corporation
- 8.6.1 Company Details
- 8.6.2 Business Overview
- 8.6.3 Product Portfolio
- 8.6.4 Financial Overview
- 8.6.5 Analysis & Outcomes
- 8.6.6 SWOT Analysis
- 8.6.7 Contact Information
- 8.7 Mercator Medsystems, Inc.
- 8.7.1 Company Details
- 8.7.2 Business Overview
- 8.7.3 Product Portfolio
- 8.7.4 Contact Information
- 8.8 Kona Medical, Inc.
- 8.8.1 Company Details
- 8.8.2 Business Overview
- 8.8.3 Product Portfolio
- 8.8.4 Contact Information
- 8.9 Cardiosonic Ltd.
- 8.9.1 Company Details
- 8.9.2 Business Overview
- 8.9.3 Product Portfolio
- 8.9.4 Contact Information
- 8.1 Ablative Solutions, Inc.
- 8.10.1 Company Details
- 8.10.2 Business Overview
- 8.10.3 Product Portfolio
- 8.10.4 Contact Information
- 8.11 SympleSurgical Inc.
- 8.11.1 Company Details
- 8.11.2 Business Overview
- 8.11.3 Product Portfolio
- 8.11.4 Contact Information
- 8.1 Cardinal Health, Inc.
- Chapter 9 Research Methodology
- 9.1 Research Methodology
- 9.2 Primary Research
- 9.3 Secondary Research
- 9.4 Report Scope
- Chapter 10 About Us
- 10.1 Who we are:
- Chapter 11 Disclaimer
- Chapter 1 Global Renal Denervation Market Overview
Inquiry Form
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!